Transforming Cancer Treatment with Category-Defining
Tumor-Activated Biologics
Voro Therapeutics is a privately held biotechnology company located in San Diego, CA. Voro’s PrimeBody technology is a best-in-class tumor-activated biologics platform that allows for systemic delivery with tumor-specific activation to safely achieve durable responses. PrimeBodies are engineered to treat a broad range of tumors with initial clinical proof-of-concept efforts focused on colorectal, gastric, prostate, and lung cancers. Voro is led by experienced oncology drug developers with deep expertise in tumor-activated therapeutics.
We are seeking aligned investors and partners for our upcoming equity round and potential co-development opportunities.
Our PrimeBody Platform
PrimeBody is an antibody-based platform that enables the development of powerful therapeutics beyond the reach of conventional approaches
We pair our finely tunable, differentiated masking technology with our best-in-class conditionally activated linkers that are efficiently cleaved by the tumor microenvironment and stay stable in serum
PrimeBodies are engineered to treat a broad range of tumors
Voro’s PrimeBody technology is a
best-in-class
tumor-activated biologics platform
Avoid on-target systemic toxicity
Conventional biologics exhibit on-target systemic toxicity and broad tissue distribution, leading to poor therapeutic index.
PrimeBodies stay masked until they reach their target tumor tissue, avoiding systemic toxicity and allowing a higher therapeutic index to be achieved.
Optimized activation linkers
Drug-like properties
Broad masking applications
Highly tunable affinity
